Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation

被引:17
|
作者
Glasser, Lewis
Meloni-Ehrig, Aurelia
Greaves, Wesley
Demel, Kurt C.
Butera, James
机构
[1] Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA
[2] Rhode Isl Hosp, Dept Hematol Oncol, Providence, RI 02902 USA
[3] Brown Med Sch, Providence, RI USA
[4] Quest Diagnost Nichols Inst, Lab Cytogenet, Chantilly, VA USA
关键词
STEM-CELL TRANSPLANTATION; BLOOD; TRANSMISSION; MALIGNANCIES;
D O I
10.1111/j.1537-2995.2008.02008.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A case of donor cell leukemia (DCL) is reported. A 42-year-old female developed acute myeloid leukemia (AML) of donor cell origin 18 months after a bone marrow transplant (BMT) from her brother. At the time DCL presented, the donor-brother was also diagnosed with AML showing identical cytogenetic abnormalities. The classification of DCL and recommendations for laboratory testing of potential hematopoietic stem cell (HSC) donors are discussed. Marrow specimens were obtained from the posterior iliac crest and analyzed using standard techniques. Leukemic cells were analyzed by flow cytometry. Karyotyping and fluorescence in situ hybridization were performed using standard methods. The recipient-sister's original diagnosis was erythroleukemia. Chromosome analysis showed a 46,XX,t(3;5)(q25;q34) karyotype. Both the recipient's new AML and the donor's AML showed an identical karyotype: 46,XY,inv(3)(q21q26),-7. Both patients were resistant to therapy and died. The clinical and biological aspects of DCL are discussed including the distinction between transformation of healthy donor cells to leukemic cells and transmission of preformed leukemic cells. The former represents almost all the reported cases of DCL compared with transmission of leukemic cells from donor to recipient. With an aging donor population, it is estimated that the latter will increase. Increased testing of older donors to include routine morphologic study of blood and marrow, cytogenetic studies, and evaluation for clonal lymphoproliferative disorders is recommended.
引用
收藏
页码:555 / 562
页数:8
相关论文
共 50 条
  • [1] Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation
    Greaves, Wesley
    Glasser, Lewis
    Meloni-Ehrig, Aurelia
    Butera, James
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (04) : 650 - 650
  • [2] DEVELOPMENT OF HYPERTHYROIDISM IN DONOR AND RECIPIENT AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    ICHIHASHI, T
    YOSHIDA, H
    KIYOI, H
    FUKUTANI, H
    KUBO, K
    YAMAUCHI, T
    NAOE, T
    OHNO, R
    BONE MARROW TRANSPLANTATION, 1992, 10 (04) : 397 - 398
  • [3] Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation
    Fores, R
    DiezMartin, JL
    Briz, M
    Cabrera, JR
    Sanjuan, I
    Regidor, C
    GarciaTalavera, J
    Fernandez, MN
    BONE MARROW TRANSPLANTATION, 1996, 17 (03) : 439 - 441
  • [4] Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: Case report and review of the literature
    Reichard, KK
    Zhang, QY
    Sanchez, L
    Hozier, J
    Viswanatha, D
    Foucar, K
    AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (03) : 178 - 185
  • [5] Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    J Mehta
    R Powles
    B Sirohi
    J Treleaven
    S Kulkarni
    R Saso
    D Tait
    S Singhal
    Bone Marrow Transplantation, 2002, 29 : 853 - 859
  • [6] Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta, J
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Saso, R
    Tait, D
    Singhal, S
    BONE MARROW TRANSPLANTATION, 2002, 29 (10) : 853 - 859
  • [7] Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta, J
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Saso, R
    Tait, D
    Singhal, S
    BONE MARROW TRANSPLANTATION, 2002, 29 : S77 - S77
  • [8] Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    Mehta, J
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Horton, C
    Saso, R
    Tait, D
    Singhal, S
    BLOOD, 2001, 98 (11) : 407A - 407A
  • [9] DONOR B-CELL LYMPHOMA OF THE BRAIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA
    VERSCHUUR, A
    BROUSSE, N
    RAYNAL, B
    BRISON, O
    ROHRLICH, P
    RAHIMY, C
    VILMER, E
    BONE MARROW TRANSPLANTATION, 1994, 14 (03) : 467 - 470
  • [10] COMPETITION BETWEEN RECIPIENT AND DONOR CELLS AFTER BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA
    FRASSONI, F
    SESSAREGO, M
    BACIGALUPO, A
    STRADA, P
    REPETTO, M
    MICELI, S
    OCCHINI, D
    DEFFERRARI, R
    MARMONT, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (04) : 471 - 475